Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

US court dances with biosimilar law's complexity in Zarxio fight

This article was originally published in SRA

Executive Summary

While the case before the US Court of Appeals for the Federal Circuit on 3 June was a dispute between Amgen and Novartis' Sandoz unit over how soon the latter firm should be able to market its biosimilar medicine Zarxio (filgrastim-sndz), it was the knotty intricacies of the Biologics Price Competition and Innovation Act (BPCIA) – the law that created the regulatory pathway for the Food and Drug Administration to approve biosimilars – that was on trial.

Advertisement
Advertisement
UsernamePublicRestriction

Register